Roy M., Lebeau L., Chessa C., Damour A., Ladram A., Oury Bruno, Boutolleau D., Bodet C., Leveque N. (2019). Comparison of anti-viral activity of frog skin anti-microbial peptides temporin-SHa and [K-3]SHa to LL-37 and temporin-Tb against herpes simplex virus type 1. Viruses - Basel, 11 (1), p. art. 77 [13 p.]. ISSN 1999-4915.
Titre du document
Comparison of anti-viral activity of frog skin anti-microbial peptides temporin-SHa and [K-3]SHa to LL-37 and temporin-Tb against herpes simplex virus type 1
Temporins are anti-microbial peptides synthesized in the skin of frogs of the Ranidae family. The few studies to date that have examined their anti-viral properties have shown that they have potential as anti-viral therapies. In this work, we evaluated the anti-herpes simplex virus type 1 (HSV-1) activity of the temporin-SHa (SHa) and its synthetic analog [K-3]SHa. Human cathelicidin LL-37 and temporin-Tb (Tb), previously demonstrated to have anti-HSV-1 properties, were used as positive controls. We observed that SHa and [K-3]SHa significantly inhibit HSV-1 replication in human primary keratinocytes when used at micromolar concentrations. This anti-viral activity was equivalent to that of Tb, but lower than that of LL-37. Transcriptomic analyses revealed that SHa did not act through the modulation of the cell innate immune response, but rather, displayed virucidal properties by reducing infectious titer of HSV-1 in suspension. In contrast, pre-incubation of the virus with LL-37 suggests that this peptide does not act directly on the viral particle at non-cytotoxic concentrations tested. The anti-HSV-1 activity of LL-37 appears to be due to the potentiation of cellular anti-viral defenses through the induction of interferon stimulated gene expression in infected primary keratinocytes. This study demonstrated that SHa and [K-3]SHa, in addition to their previously reported antibacterial and antiparasitic activities, are direct-acting anti-HSV-1 peptides. Importantly, this study extends the little studied anti-viral attributes of frog temporins and offers perspectives for the development of new anti-HSV-1 therapies.
